Search clinical trials for: Placebo to relacorilant

Total 60144 results

Corcept Therapeutics

Completed

Relacorilant Food Effect Study in Healthy Subjects

Healthy | Food-drug Interaction

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Hepatic Impairment

United States
Corcept Therapeutics

Completed

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Healthy

United States
Corcept Therapeutics

Completed

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Healthy

United States
Corcept Therapeutics

Completed

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

Healthy

United States
Corcept Therapeutics

Recruiting

Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (GRADIENT)

Hypercortisolism

United States, Austria, Bulgaria, Germany, Israel, Italy, Poland, Romania, Spain
Corcept Therapeutics

Active, not recruiting

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome (GRACE)

Cushing Syndrome

United States, Austria, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain
University of Chicago
National Cancer Institute (NCI); Corcept Therapeutics

Recruiting

Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer

Prostate Cancer

United States
Corcept Therapeutics

Enrolling by invitation

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Cushing Syndrome

United States, Austria, Bulgaria, Germany, Israel, Italy, Netherlands, Romania, Spain, Poland, Canada
Fraser Health
University of British Columbia; BC Support Unit; Ministry of Health, British... and other collaborators

Active, not recruiting

A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19 (B-EPIC)

Covid19

Canada
Corcept Therapeutics

Active, not recruiting

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Cancer

United States, Belgium, Canada, Italy, Spain
Noema Pharma AG

Recruiting

Basimglurant in Children, Adolescents, and Young Adults With TSC

Tuberous Sclerosis Complex

United States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
University of Chicago

Recruiting

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma

United States
Alyatec

Completed

Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber

Allergic Rhinitis | Rhinoconjunctivitis | Allergy to Pollen

France
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, Austria, Germany, United States, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
Corcept Therapeutics

Completed

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Healthy

United States
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Obesity

United States
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals

Recruiting

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Becker Muscular Dystrophy

United States, Italy
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

China, Germany, United States, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
KalVista Pharmaceuticals, Ltd.

Completed

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (ACI)

Knee Cartilage Lesion

Austria
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
Bayer

Recruiting

A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (SIRIUS)

Thrombolysis | Symptomatic Proximal Deep Vein Thrombosis

Belgium, France, Italy, Netherlands, Canada, Germany
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Asthma

United States, Belgium, Germany, Israel, Argentina, France, Denmark, Slovakia
KalVista Pharmaceuticals, Ltd.

Completed

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Texas Tech University
EHP Labs

Completed

Metabolic Effects of a Thermogenic Ready-to-drink Beverage

Metabolism | Metabolic Rate

United States
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Active, not recruiting

Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali (SANTE)

Stillbirths and Infant Mortality

Mali
Cardior Pharmaceuticals GmbH

Active, not recruiting

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction (HF-REVERT)

Myocardial Infarction, Acute | Heart Failure, Left Sided

Netherlands, Spain, Hungary, Germany, United Kingdom, Czechia, Poland, Greece
Bayer

Completed

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses

Hypertension | Chronic Kidney Disease

Germany, Bulgaria
AstraZeneca

Completed

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Bulgaria, Slovakia
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
Lohocla Research Corporation
National Institute on Drug Abuse (NIDA)

Recruiting

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Chronic Pain

United States
Novartis Pharmaceuticals

Terminated

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Part 1 - Healthy Volunteers | Part 2 - Patients With Hypertension

United States
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (AUGUST I)

Rheumatoid Arthritis

United States, Canada
Harvard University

Withdrawn

Mindfulness Intervention and Symptom Variability in Hearing

Hearing Loss

United States
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Xencor, Inc.
PPD; ICON plc

Completed

A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Subjects With Optic Neuritis

Optic Neuritis

United States, France, Spain, United Kingdom, Canada, Germany, Czech Republic, Belgium, Australia, Switzerland, Lebanon
Merck Sharp & Dohme LLC

Completed

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Osteoporosis
Merck Sharp & Dohme LLC

Terminated

A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)

Type 2 Diabetes Mellitus
AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States

Search clinical trials for: Placebo to relacorilant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations